These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2861549)

  • 21. Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
    Zorko N; Kojovic M; Flisar D; Pirtosek Z; Kramberger MG
    Mov Disord; 2015 Sep; 30(10):1434-5. PubMed ID: 26184074
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbidopa levodopa enteral suspension.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2015; 16(18):2807-17. PubMed ID: 26595228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of early Parkinson's disease: are complicated strategies justified?
    Ahlskog JE
    Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical inquiry. Which drugs work best for early Parkinson's disease?
    Jain L; Benko R; Safranek S
    J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
    Fernandez HH; Standaert DG; Chatamra K; Benesh JA
    Mov Disord; 2015 Sep; 30(10):1435-6. PubMed ID: 26179940
    [No Abstract]   [Full Text] [Related]  

  • 29. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Chiu S; Paulose CS; Mishra RK
    Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
    Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN; Batysheva TT; Minaeva NG; Babina LA; Vdovichenko TV; Zhuravleva EY; Shikhkerimov RK; Malykhina EA; Khozova AA; Zaitsev KA; Kostenko EV
    Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].
    Timofeeva AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(11):145-51. PubMed ID: 25629138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa-carbidopa intestinal gel (LCIG) infusion during pregnancy and delivery: first documented case.
    Zlotnik Y; Giladi N; Hilel A; Shapira Y; Goldstein S; Gurevich T
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1317-8. PubMed ID: 25262534
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of the oxytocin fragment prolyl-leucyl-glycinamide on sexual behavior in the rat.
    Gorzalka BB; Luck KA; Tanco SA
    Pharmacol Biochem Behav; 1991 Feb; 38(2):273-9. PubMed ID: 1676168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
    Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
    Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
    Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
    Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A study of combination treatment with nacom (levodopa + carbodope) and citicoline in the model of Parkinson disease in rats].
    Kashkin VA; Shekunova EV; Makarova MN; Makarov VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(7):59-63. PubMed ID: 28805762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
    Albrecht HP; Hofman HP; Klebe G; Kreiskott H
    Boll Chim Farm; 1991 Feb; 130(2):55-9. PubMed ID: 1678611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.